Search research articles
Contact Us
Filters
Showing results (51-60 of 152) with videos related to
Page
of 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1990
Pirarubicin in advanced breast cancer: a French cooperative phase II study
M Spielmann, P Kerbrat, T Delozier, et al.
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
|
April 1, 1981
[Bone metastasis revealing a hepatoma. 13 cases]
S Cottin, J P Caumon, M Gibon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 14, 2012
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes
O Humbert, A Berriolo-Riedinger, J M Riedinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 25, 2009
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours
N Isambert, M Campone, E Bourbouloux, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 1, 1984
Immunoscintigraphy of colon carcinoma
J F Chatal, J C Saccavini, P Fumoleau, et al.
Drugs
|
January 1, 1993
Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group
P Fumoleau, Y Devaux, M L Vo Van, et al.
Cancer Treatment Reports
|
June 1, 1986
Phase II clinical evaluation of doxifluridine
P Hurteloup, J P Armand, P Cappelaere, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 26, 1998
Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group
H Curé, I Krakowski, A Adenis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1996
Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group
V Urosevic, P Chollet, A Adenis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2002
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme
E Raymond, M Campone, R Stupp, et al.
Page
of 16
Search research articles
Search
Showing results (51-60 of 152) with videos related to
Sort By:
Page
of 16
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1990
Pirarubicin in advanced breast cancer: a French cooperative phase II study
M Spielmann, P Kerbrat, T Delozier, et al.
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
|
April 1, 1981
[Bone metastasis revealing a hepatoma. 13 cases]
S Cottin, J P Caumon, M Gibon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 14, 2012
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes
O Humbert, A Berriolo-Riedinger, J M Riedinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 25, 2009
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours
N Isambert, M Campone, E Bourbouloux, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 1, 1984
Immunoscintigraphy of colon carcinoma
J F Chatal, J C Saccavini, P Fumoleau, et al.
Drugs
|
January 1, 1993
Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group
P Fumoleau, Y Devaux, M L Vo Van, et al.
Cancer Treatment Reports
|
June 1, 1986
Phase II clinical evaluation of doxifluridine
P Hurteloup, J P Armand, P Cappelaere, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 26, 1998
Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group
H Curé, I Krakowski, A Adenis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1996
Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group
V Urosevic, P Chollet, A Adenis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2002
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme
E Raymond, M Campone, R Stupp, et al.
Page
of 16